Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Total Liabilities

As of the most recent data (March 2026), CYCCP shows a total liabilities of $800K. That compares with $670 in the prior-year period — up 119542.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYCCP's total liabilities is now $800K (was $670) — a 119542.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is outperforming or lagging.

Tracking CYCCP's total liabilities over time shows whether Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is scaling, shrinking, or reshaping that part of the business. The current reading is $800K That compares with $670 in the prior-year period — up 119542.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $800K) with ownership activity and broader fundamentals.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's total liabilities is $800K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.